Helus Pharma's psychedelic depression drug succeeds in late-stage study
HELP•Helus Pharma said its experimental psychedelic drug significantly improved depression symptoms compared with placebo in a late-stage trial of 222 adults. After six weeks, scores improved by 19.5 points with HLP003 versus 11.9 points with placebo.
1. Trial results
Helus Pharma said its experimental psychedelic drug HLP003 showed statistically significant improvement in depression symptoms compared with placebo in a late-stage trial involving 222 adults with moderate to severe major depressive disorder. After six weeks, patients taking HLP003 improved by 19.5 points on a standard depression scale, compared with 11.9 points for patients on placebo. Shares fell 20% in premarket trading.




